TCM
AKBA icon

Traynor Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Traynor Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Hold
14,600
– – ﹤0.01% 365
2026
Q1 		$19.3K Hold
14,600
– – ﹤0.01% 332
2025
Q4 		$23.5K Buy
+14,600
New +$30.6K ﹤0.01% 354

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
IWN
Independent Wealth Network Urbandale, Iowa $393M AUM 30.08% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return

Traynor Capital Management's AKBA Position: Q2 2026 in Review

Traynor Capital Management held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 14,600 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Traynor Capital Management first reported a position in AKBA in Q4 2025 and has held it in 3 quarters since. The position peaked at $23.5K in Q4 2025. 23 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Traynor Capital Management held 14,600 shares of Akebia Therapeutics worth $16.6K as of Q2 2026.
  • Traynor Capital Management left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Traynor Capital Management's portfolio in Q2 2026, its #365 holding.
  • Traynor Capital Management first reported a position in Akebia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Traynor Capital Management's Akebia Therapeutics position peaked at $23.5K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.